NHS Insider Buy: 6,000 Shares Added at $7.40 by Portfolio Manager
Rhea-AI Filing Summary
Form 4 highlights: On 07/17/2025, portfolio manager Chris Kocinski purchased 6,000 common shares of Neuberger Berman High Yield Strategies Fund Inc. (NHS) at a volume-weighted average price of $7.3995 (price range $7.395-$7.41). This was an open-market “P” code transaction and no shares were sold.
Following the trade, Kocinski’s direct beneficial ownership rose to 21,000 shares. No derivative securities were involved and there were no amendments to prior filings. The transaction suggests incremental insider confidence but represents a modest dollar amount (~$44k) relative to the fund’s market capitalization.
Positive
- Insider purchase: 6,000 shares acquired at $7.3995, raising ownership to 21,000 shares—often read as a confidence signal.
Negative
- None.
Insights
TL;DR: Modest insider buy; positive signal but limited capital deployed.
The Form 4 shows a small open-market purchase, increasing Kocinski’s stake by 40%. Insider buying—especially from a portfolio manager—tends to be interpreted as a vote of confidence in future NAV performance or discount narrowing. However, the absolute size is immaterial to fund liquidity and unlikely to move NHS’s share price on its own. I classify the filing as low-impact positive; it supports sentiment but offers no fundamental change to earnings, leverage, or distribution policy.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 6,000 | $7.3995 | $44K |
Footnotes (1)
- F1. The shares were purchased in separate transactions. The range of prices for the transactions reported on this line was $7.395 to $7.41. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
FAQ
What is Kocinski’s total ownership after the trade?
Was any stock sold in this Form 4?
Does the filing report any derivative securities?
AI-generated analysis. How Rhea-AI works. Not financial advice.